Navigation Links
Data to be Presented at ASCO 2007 Highlights sanofi-aventis,Commitment to Cancer Care and Research

New data on Eloxatin(R), Taxotere(R) and on three investigational agents (VEGF Trap, S-1 and TroVax(R)) will be presented at the 43rd annual ASCO meeting

BRIDGEWATER, N.J., May 29, 2007 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that a total of 375 abstracts indicative of its oncology commitment have been accepted for the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois (June 1-5, 2007). The results from key studies involving the company's leading anticancer agents, Eloxatin(R) (oxaliplatin injection) and Taxotere(R) (docetaxel injection concentrate), will be presented alongside clinical trial data examining investigational agents, aflibercept (VEGF Trap), S-1 (oral fluoropyrimidine) and TroVax(R) (Therapeutic Cancer Vaccine).

Of the abstracts which have been accepted, 129 focus on Eloxatin(R), 214 on Taxotere(R), 29 on S-1, two on VEGF Trap and one on TroVax(R). One hundred and ninety three Eloxatin(R) and Taxotere(R) abstracts were also accepted for presentation at the scientific sessions, with five Eloxatin(R) and 15 Taxotere(R) abstracts to be oral communications, including one Eloxatin(R) presentation at the ASCO plenary session.

The key results presented with Eloxatin(R)-based treatment (in combination with 5FU/LV) cover clinical trials in the adjuvant (post-surgery) colon cancer (MOSAIC study) and the metastatic (advanced) colorectal cancer (NCCTG/N9741study, EORTC40983/EPOC study) settings.

Data looking at Taxotere(R)-based regimens in adjuvant and in metastatic breast cancer will be presented during the meeting.

Two phase II studies examined aflibercept (VEGF Trap) as a single agent in recurrent ovarian and lung cancers. VEGF Trap is an anti-angiogenic agent that blocks the Vascular Endothelial Growth Factor (VEGF), and is currently being investigated to assess its use in stopping tumor growth. Aflibercept is in phase
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held medical ... an exclusive distributor agreement with ITOCHU Corporation (Tokyo Stock ... system for the treatment of cancer in ... is the world,s first and only MRI-guided radiation therapy ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo ... the federal multidistrict litigation underway in U.S. District Court, ... an Order dated January 20th, the Court has remanded ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... , KENILWORTH, N.J., Aug. 6 Schering-Plough Corporation ... its Special Shareholders Meeting being held on Friday, August 7, 2009, ... Merck & Co., Inc. Originating from Boston, the Webcast will ... www.schering-plough.com . , , Those ...
... ... Angelman Syndrome Foundation, www.angelman.org , announced the formation of the ... rapidly increasing research funding. The ATRI will also serve as a ... share discoveries and treatments for this neuro-genetic disorder. The announcement of ...
... NORTH BERGEN, N.J., Aug. 6 Vitamin Shoppe ... vitamins, minerals and nutritional products, will hold a conference call ... Eastern Time. During the call, members of management will ... , , To participate in the teleconference, ...
... , , , ... AIRM ), the largest air medical transportation company in the world, ... and provided an update on July 2009 flight volumes. For ... in the current-year quarter. For the six-month period, revenue increased ...
... EATONTOWN, N.J., Aug. 6 Osteotech, Inc. (Nasdaq: ... products for regenerative healing, announced today that its management team is ... Conference at the InterContinental Hotel in Boston on Thursday, August 13, ... live, listen-only webcast of the presentation will be available at the ...
... Study finds fewer than half always recommend the shots, ... News) -- More than half of Texas doctors don,t ... U.S. guidelines urging their inoculation, a new survey finds. ... cancer, and the national Advisory Committee on Immunization Practices ...
Cached Medicine News:Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 2Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 3Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 4Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 5Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 6Health News:Air Methods Reports 2Q2009 Results and 3Q2009 Update 7Health News:Many Texas Docs Not Pushing HPV Vaccine for Girls 2
... VHD was the first ... bleeding after diagnostic and ... procedures. It is a ... approved for immediate sheath ...
... absorbable collagen hemostat. FirstStop is a non-friable, ... removal characteristics. It can easily be cut ... wound. FirstStop products are not dispersed when ... after hemostasis is achieved. As the collagen ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
Medicine Products: